Information Provided By: 
Fly News Breaks for November 19, 2019
NVO, DRNA
Nov 19, 2019 | 07:09 EDT
H.C. Wainwright analyst Ed Arce raised his price target for Dicerna Pharmaceuticals (DRNA) to $30 from $22 after the company after announced a new strategic alliance with Novo Nordisk (NVO). The analyst sees "favorable deal terms embedded with optionality." He continues to view Dicerna as a "core, pure-play holding" in the greater nucleic acid therapy space and reiterates a Buy rating on the shares.
News For DRNA;NVO From the Last 2 Days
NVO
Apr 24, 2024 | 15:59 EDT
Senator Bernie Sanders is set to lead a Senate investigation into the high prices charged by Novo Nordisk for its diabetes and anti-obesity medications Ozempic and Wegovy, The Financial Times' Oliver Barnes reports. Sanders wrote to Novo Nordisk CEO Lars Fruergaard Jorgensen to inform him the U.S. committee that oversees healthcare is probing "the outrageously high prices" the company charges for the drugs, saying that the drugs "will not do any good for the millions of patients who cannot afford them." Reference Link
